ClinicalTrials.gg
RecruitingNCT07530302SUNCPAPUpdated Jun 17, 2026

Treatment Failure of Continuous Positive Airway Pressure (CPAP) in Patients With Obstructive Sleep Apnea Syndrome (OSA): A Trial Comparing Polysomnography and the Sunrise Device to Drive Treatment-Adjustment Decisions.

An interventional study of Sunrise in Sleep Apnea Syndrome, Obstructive, sponsored by University Hospital, Grenoble. Recruiting at 1 site in France. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-06-17.

Sponsored by University Hospital, Grenoble · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
105
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 48 studies in Sleep Apnea, Obstructive by University Hospital, Grenoble — 6 open to participants now, 6 under way, none of them phase 3. Sleep Apnea, Obstructive · University Hospital, Grenoble.

Planned enrollment
7th of 32
105 · median 54
Started
2026
with 1 other
No phase
25 of 48
4 open now
Registered
47th of 48
by date

Among the 48 studies in Sleep Apnea, Obstructive by University Hospital, Grenoble, this one is the 7th largest by planned enrollment of the 32 interventional ones that give a count, is one of 2 that started in 2026, is one of 25 with no phase, and was the 47th registered.

Sleep Apnea, Obstructive

2,246 studies on the registry are indexed under Sleep Apnea, Obstructive; 476 are open to participants now.

Browse Sleep Apnea, Obstructive studies →

Open to participants now

6 of the 48 studies in Sleep Apnea, Obstructive by University Hospital, Grenoble are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 317 Sleep Apnea, Obstructive studies recruiting now, 149 (47%) set no upper age limit and 124 (39%) stop at 75 or younger; 53 take children under 18; 66 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 48 studies in Sleep Apnea, Obstructive by University Hospital, Grenoble, or all of them as a file.
02

Study summary

The goal of this clinical trial is to determine whether treatment-adjustment decisions based on one night of home monitoring with the Sunrise device are comparable to decisions based on one night of in-laboratory polysomnography (PSG) in adults with obstructive sleep apnea (OSA) who remain insufficiently controlled with continuous positive airway pressure (CPAP) therapy.

The main questions it aims to answer are:

  • Do Sunrise-based assessments lead to similar therapeutic decisions as PSG-based assessments?
  • Are residual apnea-hypopnea indices measured by Sunrise comparable to those measured by PSG?

Participants will complete both assessment sequences in a randomized cross-over design. They will:

  • Use the Sunrise device for several nights with and without CPAP.
  • Undergo one night of PSG with and without CPAP.
  • Have their CPAP therapy reviewed based on the results of each assessment method.
Read the detailed description

Obstructive sleep apnea (OSA) affects nearly one billion adults worldwide and is associated with recurrent upper-airway obstruction during sleep, leading to intermittent hypoxemia and multiple cardiometabolic and neurocognitive comorbidities. Continuous positive airway pressure (CPAP) is the standard treatment and is widely prescribed, with more than 1.8 million users in France. Despite its proven efficacy, large-scale analyses show that over 10% of treated patients continue to exhibit elevated residual apnea-hypopnea indices (AHI), a situation associated with reduced adherence and premature discontinuation of therapy.

Evaluation of CPAP effectiveness typically relies on in-laboratory polysomnography (PSG), which remains the reference method for characterizing residual respiratory events and sleep architecture. However, the need for PSG generates substantial healthcare costs, long waiting times, and unequal access to diagnostic resources.

The Sunrise device is a CE-marked medical device that records mandibular movements during sleep and uses artificial intelligence to characterize respiratory events and sleep parameters. Multiple validation studies have demonstrated strong agreement between Sunrise-derived metrics and PSG.

This randomized cross-over trial investigates whether Sunrise can be used to guide therapeutic decisions in patients with insufficiently controlled OSA under CPAP therapy, defined by a residual AHI greater than 10 events per hour. Participants are randomized to one of two sequences:

  1. Sunrise assessments first, consisting of several nights with and without CPAP, followed by one night of PSG with and without CPAP; or
  2. PSG assessments first, followed by the Sunrise sequence.

This design allows each participant to serve as their own control and enables direct comparison of treatment-adjustment decisions derived from Sunrise versus PSG. The study aims to determine whether a home-based, low-burden assessment could replace or reduce the need for in-laboratory evaluations, thereby improving access to care, reducing costs, and facilitating personalized CPAP management.

03

Conditions studied

  • Sleep Apnea Syndrome, Obstructive

Keywords

  • Obstructive sleep apnea
  • Randomized
  • Cross-over
  • CPAP
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 18 to 85 years
  • Patients treated with Resmed CPAP
  • Residual apnea-hypopnea index under CPAP (rAHI(CPAP) > 10 events/hour)
  • Access to a smartphone and home internet connection, and ability to use a mobile application
  • Signed
  • Affiliated with, or beneficiary of, a national health insurance program

Exclusion criteria

Exclusion Criteria:

  • Severe chronic obstructive or restrictive pulmonary disease, with or without supplemental oxygen
  • Unstable cardiovascular disease or severe heart failure requiring hospitalization within the past 3 months, or meeting (NYHA) class III or IV criteria
  • Conditions affecting mandibular condyle rotation or temporomandibular joint function
  • Refusal to shave excessive facial hair when required for proper placement of the Sunrise device
  • Participation in another interventional clinical study or currently within an exclusion period of another study
  • Individuals who, in the investigator's judgment, are unlikely to comply with study procedures or requirements
  • Individuals who cannot be contacted in case of emergency
  • Persons protected under French Public Health Code articles L1121-5, L1121-6, and L1121-8 (including pregnant or breastfeeding women, persons deprived of liberty, individuals under psychiatric care under articles L.3212-1 or L.3213-1, individuals admitted to healthcare or social institutions for reasons other than research, and persons under legal protection or unable to provide )
  • Staff members with a hierarchical relationship to the principal investigator
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
105 participants (estimated)

Study arms

  • Other
    PSG-SUN

    Participants will first undergo an overnight, in-laboratory polysomnography (PSG) in the sleep center. After this in-lab recording period, they will complete an at-home sleep assessment using the Sunrise device over the predefined home recording period.

    Device: Sunrise

  • Other
    SUN-PSG

    Participants will first complete an at-home sleep assessment using the Sunrise device over the predefined home recording period. After this home recording period, they will undergo an overnight, in-laboratory polysomnography (PSG) in the sleep center.

    Device: Sunrise

Interventions

  • DeviceSunrise

    The Sunrise device is a single-use, mandibular movement-based sleep monitoring sensor designed to assess sleep architecture and respiratory events at home. In this study, Sunrise is evaluated as an alternative to in-laboratory polysomnography (PSG), which is considered the current gold-standard reference for sleep assessment.

06

What researchers measure

Primary outcomes

  1. Cohen's Kappa for Agreement Between Therapeutic Adjustment Decisions Based on Sunrise and Polysomnography (PSG)

    Agreement between therapeutic adjustment decisions derived from Sunrise home recordings and in-lab polysomnography (PSG), quantified using Cohen's kappa coefficient. Two independent experts will provide decisions for each modality; disagreements will be resolved by consensus. The therapeutic decision is a three-category variable: No change in CPAP treatment, adjustment of CPAP pressure or change of mask, switch to servo-ventilation if residual events are predominantly central.

    Time frame: Within 1 night for each modality (Sunrise home recording and in-lab PSG).

Secondary outcomes

  1. Cohen's Kappa for Agreement Between Therapeutic Adjustment Decisions Based on Three-Night Sunrise Recordings and Polysomnography (PSG)

    Agreement between therapeutic adjustment decisions derived from three consecutive nights of Sunrise home recordings and in-lab polysomnography (PSG), quantified using Cohen's kappa coefficient. Two independent experts will provide decisions for each modality; disagreements will be resolved by consensus. The therapeutic decision is a three-category variable: No change in CPAP treatment, adjustment of CPAP pressure or change of mask, switch to servo-ventilation if residual events are predominantly central.

    Time frame: Three consecutive home nights for Sunrise recordings and one in-lab PSG night.

  2. Agreement Between PSG-Measured rAHI and Sunrise-Measured rAHI (One Night and Three Nights)

    This outcome evaluates the concordance between the residual Apnea-Hypopnea Index (rAHI) measured by: * in-lab polysomnography (PSG) during one night (gold standard), * the Sunrise device during the first home night, * the Sunrise device across three consecutive home nights. For each modality, rAHI values will be interpreted by two independent experts, blinded to the results of the other method. In case of disagreement between the two experts for a given modality, they will meet to reach a consensus rAHI interpretation, following the same adjudication procedure as for the primary outcome. The analysis will compare rAHI obtained from PSG with rAHI obtained from Sunrise over one night and over three nights to assess the level of agreement between modalities.

    Time frame: One in-lab PSG night; one or three consecutive home nights with Sunrise.

  3. Inter-Rater Agreement Between the Two Independent Experts for Therapeutic Adjustment Decisions

    For each participant and for each assessment modality (in-lab PSG, one-night Sunrise recording, and three-night Sunrise recording), the therapeutic adjustment decision will be independently provided by Expert 1 and Expert 2, each blinded to the other's evaluation. The therapeutic decision is a three-category variable: * No change in CPAP treatment, * Adjustment of CPAP pressure or change of mask, * Switch to servo-ventilation if residual events are predominantly central. This outcome measures the inter-rater agreement between the two experts for each modality, based on their initial independent decisions (before any consensus meeting).

    Time frame: One in-lab PSG night; one or three consecutive home nights with Sunrise.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Sateia MJ. International classification of sleep disorders-third edition: highlights and modifications. Chest. 2014 Nov;146(5):1387-1394. doi: 10.1378/chest.14-0970. PubMed 25367475 ↗
  • Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet. 1986 Feb 8;1(8476):307-10. PubMed 2868172 ↗
  • Cassibba J, Aubertin G, Martinot JB, Le Dong N, Hullo E, Beydon N, Dupont-Athenor A, Mortamet G, Pepin JL. Analysis of mandibular jaw movements to assess ventilatory support management of children with obstructive sleep apnea syndrome treated with positive airway pressure therapies. Pediatr Pulmonol. 2024 Jul;59(7):1905-1911. doi: 10.1002/ppul.27005. Epub 2024 Apr 9. PubMed 38593278 ↗
  • Malhotra A, Martinot JB, Pepin JL. Insights on mandibular jaw movements during polysomnography in obstructive sleep apnea. J Clin Sleep Med. 2024 Jan 1;20(1):151-163. doi: 10.5664/jcsm.10830. PubMed 37767856 ↗
  • Pepin JL, Le-Dong NN, Cuthbert V, Coumans N, Tamisier R, Malhotra A, Martinot JB. Mandibular Movements are a Reliable Noninvasive Alternative to Esophageal Pressure for Measuring Respiratory Effort in Patients with Sleep Apnea Syndrome. Nat Sci Sleep. 2022 Apr 13;14:635-644. doi: 10.2147/NSS.S346229. eCollection 2022. PubMed 35444480 ↗
  • Pepin JL, Cistulli PA, Crespeigne E, Tamisier R, Bailly S, Bruwier A, Le-Dong NN, Lavigne G, Malhotra A, Martinot JB. Mandibular Jaw Movement Automated Analysis for Oral Appliance Monitoring in Obstructive Sleep Apnea: A Prospective Cohort Study. Ann Am Thorac Soc. 2024 May;21(5):814-822. doi: 10.1513/AnnalsATS.202312-1077OC. PubMed 38330168 ↗
  • Kelly JL, Ben Messaoud R, Joyeux-Faure M, Terrail R, Tamisier R, Martinot JB, Le-Dong NN, Morrell MJ, Pepin JL. Diagnosis of Sleep Apnoea Using a Mandibular Monitor and Machine Learning Analysis: One-Night Agreement Compared to in-Home Polysomnography. Front Neurosci. 2022 Mar 15;16:726880. doi: 10.3389/fnins.2022.726880. eCollection 2022. PubMed 35368281 ↗
  • Alsaif SS, Douglas W, Steier J, Morrell MJ, Polkey MI, Kelly JL. Mandibular movement monitor provides faster, yet accurate diagnosis for obstructive sleep apnoea: A randomised controlled study. Clin Med (Lond). 2024 Jul;24(4):100231. doi: 10.1016/j.clinme.2024.100231. Epub 2024 Jul 22. PubMed 39047815 ↗
  • Pepin JL, Woehrle H, Liu D, Shao S, Armitstead JP, Cistulli PA, Benjafield AV, Malhotra A. Adherence to Positive Airway Therapy After Switching From CPAP to ASV: A Big Data Analysis. J Clin Sleep Med. 2018 Jan 15;14(1):57-63. doi: 10.5664/jcsm.6880. PubMed 29198291 ↗
  • Midelet A, Borel JC, Tamisier R, Le Hy R, Schaeffer MC, Daabek N, Pepin JL, Bailly S. Apnea-hypopnea index supplied by CPAP devices: time for standardization? Sleep Med. 2021 May;81:120-122. doi: 10.1016/j.sleep.2021.02.019. Epub 2021 Feb 16. PubMed 33667996 ↗
  • Bottaz-Bosson G, Midelet A, Mendelson M, Borel JC, Martinot JB, Le Hy R, Schaeffer MC, Samson A, Hamon A, Tamisier R, Malhotra A, Pepin JL, Bailly S. Remote Monitoring of Positive Airway Pressure Data: Challenges, Pitfalls, and Strategies to Consider for Optimal Data Science Applications. Chest. 2023 May;163(5):1279-1291. doi: 10.1016/j.chest.2022.11.034. Epub 2022 Dec 2. PubMed 36470417 ↗
  • Pepin JL, Bailly S, Rinder P, Adler D, Szeftel D, Malhotra A, Cistulli PA, Benjafield A, Lavergne F, Josseran A, Tamisier R, Hornus P, On Behalf Of The medXcloud Group. CPAP Therapy Termination Rates by OSA Phenotype: A French Nationwide Database Analysis. J Clin Med. 2021 Mar 1;10(5):936. doi: 10.3390/jcm10050936. PubMed 33804319 ↗
  • Liu D, Armitstead J, Benjafield A, Shao S, Malhotra A, Cistulli PA, Pepin JL, Woehrle H. Trajectories of Emergent Central Sleep Apnea During CPAP Therapy. Chest. 2017 Oct;152(4):751-760. doi: 10.1016/j.chest.2017.06.010. Epub 2017 Jun 16. PubMed 28629918 ↗
  • Levy P, Kohler M, McNicholas WT, Barbe F, McEvoy RD, Somers VK, Lavie L, Pepin JL. Obstructive sleep apnoea syndrome. Nat Rev Dis Primers. 2015 Jun 25;1:15015. doi: 10.1038/nrdp.2015.15. PubMed 27188535 ↗
  • Benjafield AV, Ayas NT, Eastwood PR, Heinzer R, Ip MSM, Morrell MJ, Nunez CM, Patel SR, Penzel T, Pepin JL, Peppard PE, Sinha S, Tufik S, Valentine K, Malhotra A. Estimation of the global prevalence and burden of obstructive sleep apnoea: a literature-based analysis. Lancet Respir Med. 2019 Aug;7(8):687-698. doi: 10.1016/S2213-2600(19)30198-5. Epub 2019 Jul 9. PubMed 31300334 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Sep 2029, 39 months after the start.

Of 511 non-industry interventional studies with no phase under Sleep Apnea, Obstructive, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 53. This study's planned 39 months is above that.

Counting every sponsor, half of 629 studies reached it within 27 months; a quarter within 12 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 30, 2026
First posted
Apr 15, 2026
StartActual
Jun 10, 2026
Primary completionEst.
Sep 2029
CompletionEst.
Sep 2029
Last update
Jun 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07530302
Collaborators
Polyclinique Saint Laurent - Rennes
Responsible party
Sponsor
First posted
Apr 15, 2026
Start date
Jun 10, 2026
Primary completion
Sep 2029 (estimated)
Completion
Sep 2029 (estimated)
Last update
Jun 17, 2026

Study contacts

Marie JOYEUX-FAURE, Pr
Contact
MJoyeuxfaure@chu-grenoble.fr
+33(0)476767166

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion